A detailed history of Graham Capital Management, L.P. transactions in Nektar Therapeutics stock. As of the latest transaction made, Graham Capital Management, L.P. holds 19,057 shares of NKTR stock, worth $17,723. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,057
Previous 27,345 30.31%
Holding current value
$17,723
Previous $33,000 27.27%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.11 - $1.48 $9,199 - $12,266
-8,288 Reduced 30.31%
19,057 $24,000
Q2 2024

Aug 14, 2024

BUY
$0.9 - $1.83 $24,610 - $50,041
27,345 New
27,345 $33,000
Q2 2023

Aug 14, 2023

SELL
$0.53 - $1.03 $313,125 - $608,526
-590,802 Reduced 96.08%
24,095 $13,000
Q1 2023

May 15, 2023

BUY
$0.64 - $3.15 $117,120 - $576,450
183,000 Added 42.37%
614,897 $430,000
Q4 2022

Feb 14, 2023

BUY
$2.03 - $4.28 $218,308 - $460,275
107,541 Added 33.16%
431,897 $976,000
Q3 2022

Nov 14, 2022

BUY
$3.04 - $5.14 $208,498 - $352,526
68,585 Added 26.82%
324,356 $1.04 Million
Q2 2022

Aug 15, 2022

BUY
$3.17 - $6.17 $456,315 - $888,159
143,948 Added 128.73%
255,771 $971,000
Q1 2022

May 16, 2022

BUY
$4.16 - $13.72 $465,183 - $1.53 Million
111,823 New
111,823 $602,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.